Summit Therapeutics SMMT Accrued Manufacturing Costs
Accrued Manufacturing Costs at other companies
Other financials
Where this comes from
Reported directly by Summit Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:EmployeeRelatedLiabilitiesCurrent.
The official record: Summit Therapeutics’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →
Ask your AI about Summit Therapeutics's accrued manufacturing costs.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Summit Therapeutics's accrued manufacturing costs?
- Summit Therapeutics (SMMT) reported accrued manufacturing costs of $7.07M in Q1 2026.
- How has Summit Therapeutics's accrued manufacturing costs changed year-over-year?
- Summit Therapeutics's accrued manufacturing costs increased by 60.9% year-over-year, from $4.4M to $7.07M.
- What is the long-term trend for Summit Therapeutics's accrued manufacturing costs?
- Over 5 years (2020 to 2025), Summit Therapeutics's accrued manufacturing costs has grown at a 72.3% compound annual growth rate (CAGR), from $983K to $14.93M.